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In Switzerland 319 of 594 young women seronegative for rubella antibody vaccinated at
15-25 years of age against rubella with the Cendehill vaccine strain were retested 15 years
later with three tests (hemagglutination inhibition, enzyme-linked immunosorbent assay,
and a neutralization technique) for the presence of rubella antibodies. For 307 women
rubella antibodies were still detectable by all three techniques. For nine women rubella
antibodies were demonstrable by only one or two tests. Only three vaccinees were
seronegative by all three tests. These three women also showed no booster response after
challenge with the vaccine strain. The high percentage of women with persistent rubella
antibodies 15 years after vaccination might be explained in part by the presence of sub-
clinical reinfections due to a wild rubella virus.
In Switzerland, as in other European countries, im-
munization against rubella has been particularly.
advocated for girls while they are still in school so
as to directly protect the population at risk. For Eu-
ropeans one of the reasons for not immunizing in-
fants, as has been the practice in the United States,
was the uncertain persistence of the rubella vac-
cine-induced immunity. Studies evaluating levels
of rubella antibodies ~12 years after rubella vacci-
nation are either lacking or are based on small
numbers of vaccinees. In Basel, rubella immuniza-
tions were already started on an experimental basis
in the fall of 1967 on a fairly large scale.
In 1983, we had the opportunity to test >300
rubella antibody-seronegative vaccinees for levels
of various humoral antibodies (hemagglutination
inhibition [HAl], ELISA, neutralization) 15 years
after immunization. The few women without anti-
bodies or with doubtful immunity were challenged
with the Cendehill strain of vaccine virus.
Study Program and Methods
Vaccinees. Testing of schoolgirls while they are
still in school (at the age of 14-19 years) for rubella
immunity was started in Basel in the fall of 1967.
Besides schoolgirls, women training to be nurses and
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kindergarten teachers were also screened [1, 2]. For
economic reasons, in the spring of 1969, pretesting
for the presence of rubella antibody before immu-
nization was discontinued in the schools.
Between the fall of 1967 and the spring of 1969,
>600 rubella antibody-seronegative young women
were identified. Most of them were immunized with
the Cendehill vaccine. For most vaccinees a second
blood sample - already taken four weeks after the
immunization with the Cendehill vaccine- was avail-
able. Of the vaccine-induced seroconverters, 594were
included in our evaluation program.
In the late summer and fall of 1983(15 years after
the Cendehill vaccination), blood samples weretaken
from 319 (54070) of the 594 vaccinees. None of the
vaccinees had a history of clinical rubella or rubella-
like illness or of a second rubella vaccination in the
period between the vaccination and the tests done
15 years later.
Rubella vaccines. In the 1967-1969period, only
Cendehill vaccine [3, 4] produced by Smith Kline-
RIT (Rixensart, Belgium) was available. The same
Cendehill vaccine strain was used for the challenge
studies.
Challenge study. The women lacking immunity
or having doubtful immunity were challenged by im
injection of the Cendehill vaccine strain. Blood was
drawn from these women just before challenge and
one, two, and six weeks later.
Evaluation ojthe rateojnaturalreinjection. As
already mentioned, the first antibody control test in
the vaccinees was done four weeks after immuniza-
tion. In 1967-1968 wedid not yet know that the peaks
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serum antibody level after Cendehill vaccination is
reached only after an interval of six to 12 weeks [5].
Thus we cannot directly compare the postimmuni-
zation antibody titers with those measured in the
blood samples taken 15 years later. From a portion
of our vaccinees, several serum samples were received
during the 15-yearperiod. For all vaccinees for whom
at least six serum samples (not including the prevac-
cination and the first postvaccination samples) were
available, frozen (- 20 C) sera were thawed, and all
samples - including the 1983 serum - were simul-
taneously tested by the HAl method.
Rubellaantibody tests. In the 1967-1969period,
preimmunization and first postimmunization blood
samples were evaluated only by the HAl technique.
But when the first postimmunization serum was
tested, the preimmunization sample was always si-
multaneously reevaluated. All serum samples taken
in 1983were examined by the HAl and ELISA tech-
niques. Most of these sera (especially those with rel-
atively low titers) were also evaluated by the neutrali-
zation method. All the sera of the challenge study
were checked not only for total or IgG antibodies
but also for specific IgM antibodies.
Tests for total and IgO rubellaantibodies. HAl
tests were carried out as described by Herrmann et
a1. [6]. Nonspecific inhibitors were removed with
heparin and MnC1. Pigeon erythrocytes were used
within one to two days of collection.
The ELISA used for detection of IgG rubella an-
tibodies was performed with the commercial Ruba-
zyme diagnostic kit (Abbott Laboratories, North
Chicago, 111.).
Neutralization tests were carried out as reported
by Herrmann et a1. [6] with the following modifica-
tions. Vero cells were grown in glass tubes for four
days. Rubella virus (0.5 ml) strain 8238 [7] at a dilu-
tion of 50 TCIDsolml was mixed with 0.5 ml of
diluted serum- TC 199 medium being the diluent
in both cases - and incubated for 1 hr at 37 C. The
above serum-virus mixture (0.2 ml) was inoculated
in the glass tubes with the Vero cells. The tubes were
incubated for seven days at 37 C. Viral multiplica-
tion or its inhibition by serum was assayed by in-
direct immunofluorescence as described by Schilt [7].
Tests for IgM rubella antibodies. In the HAl test,
the serum to be tested was first separated by gel filtra-
tion on agarose, as described by Burgin-Wolff et a1.
[8]. The IgM fraction was tested in the usual HAl
setup. In the ELISA, the presence of IgM antibod-
ies was determined with the Rubazyme-M diagnos-
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tic kit produced commercially by Abbott. The pres-
ence of IgM antibodies was also determined by the
M-antibody capture RIA (MACRIA) method of
Mortimer et a1. [9].
For comparison of titers an international control
serum, made available to us by Dr. P. S. Gardner
(Colindale, England), was included in our test series.
Results
Long-term evaluation ofvaccine-inducedantibod-
ies. Of the 319 women tested 15 years after immu-
nization with the Cendehill vaccine, 307 were still
seropositive for antibodies by all three tests. Three
(10,10) were seronegative by all three tests. For nine
women we consider immunity doubtful because one
or two of the tests gave a negative result.
Challenge study. The three seronegative women
(results of all antibody tests were negative) and seven
of the women with doubtful immunity (results of
one or two of the tests were negative) were challenged
with the Cendehill vaccine strain. Women with
proven immunity (results of all three tests were still
positive 15years after the vaccination) were not chal-
lenged.
Table 1summarizes the IgG and IgM antibody re-
sponses of the women after challenge. All three
seronegative women showed a "primary vaccine reac-
tion": no antibodies were found until more than
seven days after challenge. IgM antibodies were de-
tectable after challenge by all three tests. For one vac-
cinee, IgM rubella antibodies were found after two
weeks, and in two vaccinees, in the third blood sam-
ple after challenge. All seven women with doubtful
immunity showed some kind of a "memory reaction"
after challenge. In none of these seven were rubella
IgM antibodies detectable by any test, but all women
showed some increase in the rubella IgG antibody
titer.
Subclinical reinfections. For 94 of the vaccinees,
at least six serum samples were collected during the
15-year period. For nine of these women, a signifi-
cant increase in antibody levelswas observed, a find-
ing which suggests that for at least 10% of the vac-
cinees a subclinical reinfection must have occurred.
Discussion
All studies on the persistence of vaccine-induced
rubella antibodies have shown a high percentage of
vaccinees with persistence of immunity as measured
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Table 1. Antibody response of women with negative
or doubtful immunity to rubella 15 years after vaccina-
tion on challenge with Cendehill vaccine strain.
No. of women positive for indicated type
Category of of rubella antibody by test
immunity results Neutral-
(no. of women), HAI* ELISAt MACRIAt izationll
no. of days
after challenge All IgM IgG IgM IgM All
Negative (3)
0 0 0 0 0 0 0
7 0 0 0 0 0 0
14 1 2 0 1 1 1
42 3 ND 3 2§ 2§ 3
Doubtful (7)
0 4 0 4 0 0 2
7 4 0 4 0 0 5
14 7 0 7 0 0 6
42 7 ND 7 0 0 7
NOTE. Negative category denotes absence of rubella anti-
bodies by three tests (HAl, ELISA, neutralization) before
challenge. Doubtful category denotes presence of rubella anti-
bodies by one or two of these three tests before challenge.
Abbreviations: HAl = hemagglutination inhibition; MACRIA
= M-antibody capture RIA; ND = not determined.
* Positive result indicated by the presence of ~5 IV of ru-
bella antibodies/ml or a titer of ~1:8.
t Positive result indicated by the presence of ~10 IV of
rubella antibodies/ml.
t Positive result indicated by a binding ratio of test to nega-
tive serum of >2 [9].
II Positive result indicated by the presence of ~5 IV of rubel-
la antibodies/ml or by a titer of ~1:2.
§ The woman who was IgM-positive on day 14 was IgM-
negative at day 42.
by tests of humoral antibody (e.g., [10-12]). But we
weresurprised that in our long-term study only three
(1070) of 319 women had lost all rubella antibodies
15years after immunization with Cendehill vaccine.
For 307 (96.2070) of the 319women, rubella antibod-
ies were still detectable by all three test methods.
These surprising results reflect either methodologic
errors, the way in which the sample was collected,
or a unique epidemiologic situation. Methodologic
errors can be excluded, chiefly because the results
were similar when different tests were used. Fifteen
years after the vaccination we could trace only 54%
of the original study group. However, it is not sur-
prising that the percentage is this low because most
vaccineeshad changed not only their address but also
their family name by marriage. In Switzerland no
official proposals for rubella revaccinations have
been published. Therefore, it is unlikely that a sig-
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nificant number of our vaccinees had received a sec-
ond rubella immunization. The exact number of
rubella cases in Switzerland in the last 15 years is
not known. However, a significant decrease in the
number of childhood rubella cases has not occurred.
It is likely that a portion of our vaccinees had had
a subclinical natural rubella infection; in 10070 of our
study group, such a reinfection was proved by a sig-
nificant increase in antibody levels. Because a suffi-
cient number of serum samples from the same in-
dividual vaccinee could not be obtained throughout
the IS-year period, the measured reinfection rate of
10070 is the minimal rate of possible reinfections.
The essential result, namely that only 1070 of the
vaccinees lost antibody after 15years, shows that at
least under the epidemiologic conditions of the last
15 years, the immunity induced by rubella vaccina-
tion - even with the Cendehill vaccine - is a long-
lasting one.
The epidemiologic situation regarding rubella in
Switzerland and in all other European countries is
not the same as that in the United States. In Europe,
the chance of rubella-vaccinated adults coming into
contact with children infected with wild rubella vi-
rus is still high. The high percentage of women with
persistent rubella immunity 15 years after vaccina-
tion could therefore be explained in part by a his-
tory of subclinical reinfection.
When a policy of rubella vaccinations for children
is enforced in Europe, the risk of subclinical rein-
fections for vaccinees will decrease. In Germany it
is officially recommended that all girls vaccinated
against rubella in infancy be revaccinated at the on-
set of puberty [13]. Whether such general, uncon-
trolled rubella revaccinations are really needed must
be evaluated by testing for long-term persistence of
antibodies to rubella in countries with a low inci-
dence of childhood rubella, such as the United
States.
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